NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01479036,"Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer",https://clinicaltrials.gov/study/NCT01479036,CBCRT01,UNKNOWN,This study was designed to determine the efficacy and safety of neoadjuvant docetaxel and epirubicin (DE) with or without human recombinant endostatin (endostar) for breast cancer patients. The hypothesis of this protocol is that a combined angiogenesis inhibiting therapy to chemotherapy could further benefit breast cancer patients.,NO,Breast Cancer,DRUG: docetaxel and epirubicin|DRUG: docetaxel and epirubicin plus endostatin,"Clinical/pathological response, The clincial response will be evaluated according to RECIST criteria. The parameters of tumor metabolism and blood supply, as demonstrated by PET, MRA and CEUS, will be collected and analysed., 3 years","Number of participants with adverse events, The number of participants with adverse events will be recorded and analysed., 3 years|Quality of life, Quality of life is scored using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life of Questionnaire (QLQ30) at study entry and prior to surgery., 3 years|Number of adverse events reported during neoadjuvant therapy, The adverse events during neoadjuvant therapy will be graded using the National Cancer Institute Common Toxicity Criteria (NCI CTC) version 2.0., 3 years",,Xijing Hospital,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,800,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT,Endostar B-02|CBCRT01,2011-10,2014-12,2015-02,2011-11-24,,2011-11-24,"Xijing Hospital, Xi'an, Shaanxi, 710032, China",
